PharmaCyte Biotech (PMCB) Shares Outstanding (2010 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Shares Outstanding (Entity) of $8.4 million for Q2 2026, up 14.31% year-over-year from $7.3 million in Q2 2025, and down 9.55% quarter-over-quarter from $9.3 million in Q1 2026.
PharmaCyte Biotech (PMCB) Shares Outstanding (2010 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Shares Outstanding (Entity) for 17 consecutive years, with $8.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) rose 14.31% year-over-year to $8.4 million; the TTM figure through Apr 2026 stood at $8.4 million (up 14.31% YoY), while the FY2026 annual figure was $8.4 million, up 14.31% from the prior year.
- Shares Outstanding (Entity) eased to $8.4 million in Q2 2026 per PMCB's latest filing, from $9.3 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $21.6 million in Q4 2022 and bottomed at $6.8 million in Q3 2025.
- Historically, Shares Outstanding (Entity) has averaged $12.4 million across 5 years, with a median of $9.0 million in 2023.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) surged 1240.35% — and 2024, when it plunged 60.16%.
- PharmaCyte Biotech's Shares Outstanding (Entity) stood at $21.6 million in 2022, then tumbled by 59.42% to $8.8 million in 2023, then dropped by 12.87% to $7.6 million in 2024, then decreased by 11.02% to $6.8 million in 2025, then gained by 23.29% to $8.4 million in 2026.
- Business Quant data shows PMCB's Shares Outstanding (Entity) at $8.4 million in Q2 2026, $9.3 million in Q1 2026, and $6.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 8.38 Mn |
| Jan 31, 2026 | 9.26 Mn |
| Oct 31, 2025 | 6.80 Mn |
| Jul 31, 2025 | 6.80 Mn |
| Apr 30, 2025 | 7.33 Mn |
| Jan 31, 2025 | 6.96 Mn |
| Oct 31, 2024 | 7.64 Mn |
| Jul 31, 2024 | 7.87 Mn |
| Apr 30, 2024 | 9.58 Mn |
| Jan 31, 2024 | 8.61 Mn |
| Oct 31, 2023 | 8.77 Mn |
| Jul 31, 2023 | 12.60 Mn |
| Apr 30, 2023 | 19.49 Mn |
| Jan 31, 2023 | 19.00 Mn |
| Oct 31, 2022 | 20.59 Mn |
| Jul 31, 2022 | 20.83 Mn |
| Apr 30, 2022 | 15.52 Mn |
| Jan 31, 2022 | 21.67 Mn |
| Oct 31, 2021 | 17.36 Mn |
| Jul 31, 2021 | 1.59 Mn |